Apextide Co., Ltd

Apextide Co., Ltd is a leading pharmaceutical manufacturing company specializing in providing comprehensive CDMO (Contract Development and Manufacturing Organization) services for oligonucleotides, small molecules, and peptides. As a subsidiary of Sinopep Biotech (stock code 688076), Apextide leverages over a decade of successful experience in process development to offer services spanning from preclinical research to commercial manufacturing.

Apextide's expertise lies in its cutting-edge oligonucleotide and peptide platforms, equipped with advanced international CYTIVA equipment. This infrastructure enables the company to provide a "one-stop" manufacturing service, encompassing laboratory research and development, process development, clinical stage scale-up production, and commercialization. Apextide supports production scales from gram level to kilogram level, ensuring flexibility and scalability for its clients. Furthermore, Apextide utilizes advanced analytical facilities, including QHPLC/UPLC, LC-MS, LC-MS/MS, IC, GC, GC-MS, and ICP-MS, to guarantee the structural integrity, analytical method development, GMP production control, and final product release testing of its products.

Apextide's dedicated process, analysis, formulation, and regulatory teams work collaboratively to deliver fast, efficient, professional, and flexible integrated solutions throughout the entire oligonucleotide development process. Apextide is committed to meeting both domestic and international regulatory requirements, providing customers with high-quality GMP production services for preclinical sample preparation, oligonucleotide APIs, and related preparations. The information provided will be completed soon with the support of the company’s management.

To the manager of Apextide Co., Ltd, we invite you to create a customized and exclusive company showcase and product listing on our platform to further enhance your company's visibility and commercial reach.